Successful management of neonatal shock is driven by the etiology and pathophysiology of the cardiovascular compromise. In the clinical practice, however, we only have a limited ability to recognize the etiology of the condition (hypovolemia, myocardial dysfunction or abnormal vasoregulation). Therefore, management is based on administration of fluid boluses and vasoactive medications according to personal preference rather than to the underlying pathophysiology. In addition, although management strategies aimed at improving systemic blood pressure may have been associated with a decrease in mortality in critically ill neonates, there are no prospective data on the effect of these management strategies on morbidity, especially on long-term neurodevelopmental outcome. This paper briefly reviews some of the more frequently encountered clinical presentations of neonatal shock and describes the developmentally regulated cardiovascular responses to the pathophysiology-driven management strategies used in these clinical presentations in the critically ill preterm and term neonate. Vasoactive amines are frequently used in the treatment of hypotensive neonates and, in the case of dopamine and to a lesser extent dobutamine, there is some understanding about their developmentally regulated mechanisms of action.
Vasoactive amines are frequently used in the treatment of hypotensive neonates and, in the case of dopamine and to a lesser extent dobutamine, there is some understanding about their developmentally regulated mechanisms of action. 1, 2 However, there is no direct evidence indicating that the use of these pressors/ inotropes improves mortality and/or outcome in the neonatal population. 1, 3 One of the most frequently asked questions related to the use of these medications during rounds is whether there is a given drug or a combination of drugs that would effectively treat hypotension and thus normalize organ blood flow across gestational and postnatal age ranges and clinical presentations. Unfortunately, the answer is no, and this paper discusses three major reasons why it is impossible to prescribe a simple formula to treat neonatal shock. They are as follows:
(1) in the very low birth weight (VLBW) neonate, during the immediate postnatal period, blood pressure may be a poor indicator of cerebral blood flow (CBF); (2) treatment must be tailored to the etiology and pathophysiology of neonatal shock; (3) severe illness and relative adrenal insufficiency alter cardiovascular adrenergic receptor expression and thus myocardial function and regulation of organ blood flow making it difficult to predict the given patient's response to treatment.
A detailed discussion on the mechanisms of action of vasoactive medications and the limitations of continuous organ blood flow monitoring at the bedside is beyond the scope of this paper, and the reader is referred to recent publications on these topics. [1] [2] [3] [4] [5] (1) Relationship between blood pressure and CBF in the VLBW neonate during the immediate postnatal period: Recent studies on the hemodynamic changes in VLBW neonates during the first 24 hours of extrauterine life using measurements of superior vena cava flow as a surrogate measure of cerebral blood flow found that a significant number of these patients develop periods of a low flow state. [6] [7] [8] The findings of these studies indicate that the more immature the neonate, the higher the likelihood of low CBF with over 70% of 23-to 25-week gestation neonates being affected; that low CBF normalizes in all patients surviving into the second postnatal day; that intraventricular hemorrhage (IVH) occurs when CBF normalizes suggesting hypoperfusion-reperfusion in the pathogenesis of IVH; and that neither dopamine nor dobutamine is very effective at reversing the low flow state. Furthermore, some neonates presenting with low CBF remain ''normotensive'' during the low flow state suggesting that, in these patients, blood pressure in the accepted ''normal'' range 9 does not guarantee normal CBF. Since the brain is a vital organ, its blood flow by definition may only decrease in the uncompensated phase of shock, that is, when hypotension develops. Therefore, the observation of cerebral hypoperfusion in the face of normal blood pressure defies the basic rules of cardiovascular physiology. However, if one accepts that the lower limit of the gestational-and postnatal-age-dependent ''normal'' blood pressure range used in these studies is correct, a potential explanation for the apparent dissociation of CBF autoregulation from systemic blood pressure in the extremely low birth weight (ELBW) neonate is that the cerebral cortex may be a nonvital organ with low-priority vascular beds, which respond to impending shock with vasoconstriction rather than vasodilation. Indeed, findings of a recent study of high cerebral fractional oxygen extraction in ELBW neonates during the first 24 postnatal hours suggest that hemispheric blood flow is reduced in many ELBW neonates to maintain blood pressure in the face of decreased cardiac output. 10 It appears that by the second to third postnatal day, CBF autoregulation normalizes in the ELBW neonate, but the cellular mechanisms of vital organ assignment during development and in response to premature delivery are unknown. At present, the use of milrinone to prevent the occurrence of low CBF during the first postnatal day is being evaluated in this patient population.
(2) For effective management of neonatal shock, treatment must be tailored to the primary etiology and thus the pathophysiology of neonatal shock: Although this statement appears self-explanatory, it is often difficult to identify the primary etiology of shock (hypovolemia, myocardial dysfunction or abnormal vasoregulation; or a combination of two or more of the primary etiologic factors). Although absolute hypovolemia is rarely the primary cause of shock in the neonate immediately after delivery, it may become a more frequent primary factor during the next few days such as seen with excessive transepidermal fluid losses in the ELBW neonate or with increased enteral fluid flosses in the surgical preterm and term neonate. The treatment is replacement of the type of fluid lost. Myocardial dysfunction leading to hypotension may occur in neonates with perinatal depression and peri-or postnatal viral or bacterial infection or, in the ELBW neonate, during the immediate postnatal period.
Treatment of these cases includes avoidance of extra fluid administration and judicious use of inotropes (dobutamine) or lusitropes (milrinone) if peripheral vascular resistance is elevated.
In cases with abnormal peripheral vasoregulation (any neonate with inflammatory response syndrome such as sepsis, NEC, etc), the use of pressors (dopamine or epinephrine) will target the primary hemodynamic abnormality (vasodilation) and address the potential myocardial dysfunction. In these cases, however, attention must be paid to ensure that stroke volume is maintained in the face of the increased systemic vascular resistance. If this is not the case, blood pressure may normalize in response to the druginduced peripheral vasoconstriction but tissue perfusion could still be compromised. Short of functional echocardiography, thorough monitoring of the acid-base status and lactate levels may help addressing this issue. (3) Severe illness and relative adrenal insufficiency alter cardiovascular adrenergic receptor expression and vasoregulation: Expression of adrenergic receptors and intracellular signaling systems is developmentally regulated. 1 It has been shown that beta-receptor maturation lags behind that of the alpha-receptors and that there is an alpha-receptor dominance in the hemodynamic response to the administration of sympathomimetic amines in the preterm neonate. 1 However, a downregulation of both alpha-and beta-adrenergic receptors and second messengers systems occurs in cases of critical illness and exogenous catecholamine administration. 11 Indeed, adrenergic receptor downregulation as well as relative adrenal insufficiency 12 have recently been suggested as causative factors 3, 4, 13 for the development of pressor-resistant hypotension, especially in the sick preterm neonate. Since expression of the cardiovascular adrenergic receptors and some components of their second messenger systems is inducible by glucocorticoids, 11 steroid administration offers a powerful clinical tool to reverse the effects of receptor downregulation and treat the relative or absolute adrenal insufficiency. 13 Interestingly, the recently described rapid improvement in cardiovascular function (1 to 2 hours) following hydrocortisone administration 13 cannot be explained solely by the genomic effects of steroids (synthesis and membrane-assembly of new receptor proteins) as these effects likely take several hours to occur. The rapid response may rather be due to the nongenomic actions of steroids, which increase the sensitivity of the cardiovascular system to catecholamines without delay. 13 In addition, steroids inhibit prostacyclin production and the induction of iNOS, 14 limiting the pathological vasodilation associated with the inflammatory response in the critically ill neonate. Finally, by improving capillary integrity, steroid administration may also increase the effective circulating blood volume. Whether the use of a brief course of low-dose hydrocortisone to treat pressor-resistant hypotension in the preterm neonate is associated with an increased risk of abnormal brain development or infection is unknown. However, steroid (dexamethasone or low-dose hydrocortisone) use in the ELBW during the first postnatal week appears to be associated with an increased risk of ileal perforation, especially in patients treated with indomethacin. 15, 16 It is unknown whether this is a cumulative dose-dependent effect or even a brief exposure to low-dose steroids and indomethacin results in this complication. In summary, a thorough understanding of the underlying etiology and pathophysiology of neonatal shock, an appreciation of the different approaches required to treat hypotensive neonates with different clinical presentations and knowledge of the developmentally regulated pharmacodynamic actions of pressors, intoropes and lusitropes are necessary in the management of the hypotensive neonates. Finally, this review will end with the notion that data documenting causation rather than association between effective treatment of hypotension (and organ hypoperfusion) and improved outcome have not been produced as yet.
